This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Copyright Permission Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Makanji, Y. Articles by Robertson, D. M. Search for Related Content PubMed PubMed Citation Articles by Makanji, Y. Articles by Robertson, D. M.

Inhibin A and B in Vitro Bioactivities Are Modified by Their Degree of Glycosylation and Their Affinities to Betaglycan

Prince Henry’s Institute of Medical Research (Y.M., C.A.H., P.G.S., D.M.R.) and Department of Obstetrics and Gynaecology (Y.M.), Monash University, Clayton, Victoria 3168, Australia; and DSL-Beckman Coulter (R.K.), Webster, Texas 77598

Address all correspondence and requests for reprints to: David M. Robertson, Ph.D., Prince Henry’s Institute of Medical Research, PO Box 5152, Clayton, Victoria 3168, Australia. E-mail: david.robertson{at}princehenrys.org.

Inhibin A and B, important regulators of normal function in tissues of the reproductive axis, are glycosylated at either Asn²⁶⁸ or Asn²⁶⁸ and Asn³⁰² in the -subunit to produce 31- and 34-kDa isoforms, respectively. In this study, glycosylated isoforms of recombinant human inhibin A and B were purified from conditioned medium using immunoaffinity chromatography and reversed-phase HPLC. The masses of the purified inhibin preparations were determined by several inhibin immunoassays, and their in vitro bioactivities were based on suppression of FSH release by rat pituitary cells in culture. Based on a ratio of in vitro bioactivity to immunoactivity (B:I ratio), the monoglycosylated 31-kDa inhibin A was 5-fold more potent than the diglycosylated 34-kDa inhibin A (B:I ratio, 1.22 ± 0.15 vs. 0.24 ± 0.05; P < 0.001, respectively). The 31-kDa inhibin B was significantly (P < 0.001) more potent (1.75 ± 0.29) than the 34-kDa form (1.08 ± 0.20). Because inhibin biological activity is dependent upon interactions with the coreceptor betaglycan, the effect of inhibin glycosylation on betaglycan binding was assessed. Analogous to the pattern of in vitro bioactivity, 31-kDa inhibin A was 12-fold more active (IC₅₀, 0.68 nM) than the 34-kDa isoform (IC₅₀, 8.2 nM) at displacing [¹²⁵I]inhibin A from COS7 cells expressing betaglycan. However, the 1.6-fold difference in bioactivity of the inhibin B isoforms was not matched by differences in their affinities for betaglycan. It is concluded that glycosylation of Asn³⁰² of the -subunit of inhibin A and B results in a decrease in bioactivity, and the effect on inhibin A, at least, is explained by its reduced affinity to betaglycan.

This article has been cited by other articles:

				Y. Makanji, P. D. Temple-Smith, K. L. Walton, C. A. Harrison, and D. M. Robertson Inhibin B Is a More Potent Suppressor of Rat Follicle-Stimulating Hormone Release than Inhibin A in Vitro and in Vivo Endocrinology, October 1, 2009; 150(10): 4784 - 4793. [Abstract] [Full Text] [PDF]

				A.L. Chand, C.A. Harrison, and A.N. Shelling Inhibin and premature ovarian failure Hum. Reprod. Update, September 14, 2009; (2009) dmp031v1. [Abstract] [Full Text] [PDF]

				Y. Wang, P. K Nicholls, P. G Stanton, C. A Harrison, M. Sarraj, R. B Gilchrist, J. K Findlay, and P. G Farnworth Extra-ovarian expression and activity of growth differentiation factor 9 J. Endocrinol., September 1, 2009; 202(3): 419 - 430. [Abstract] [Full Text] [PDF]

				E. Wiater, K. A. Lewis, C. Donaldson, J. Vaughan, L. Bilezikjian, and W. Vale Endogenous Betaglycan Is Essential for High-Potency Inhibin Antagonism in Gonadotropes Mol. Endocrinol., July 1, 2009; 23(7): 1033 - 1042. [Abstract] [Full Text] [PDF]

				P. K. Nicholls, C. A. Harrison, R. B. Gilchrist, P. G. Farnworth, and P. G. Stanton Growth Differentiation Factor 9 Is a Germ Cell Regulator of Sertoli Cell Function Endocrinology, May 1, 2009; 150(5): 2481 - 2490. [Abstract] [Full Text] [PDF]

				K. L. Walton, Y. Makanji, M. C. Wilce, K. L. Chan, D. M. Robertson, and C. A. Harrison A Common Biosynthetic Pathway Governs the Dimerization and Secretion of Inhibin and Related Transforming Growth Factor {beta} (TGF{beta}) Ligands J. Biol. Chem., April 3, 2009; 284(14): 9311 - 9320. [Abstract] [Full Text] [PDF]

				Y. Makanji, K. L. Walton, M. C. Wilce, K. L. Chan, D. M. Robertson, and C. A. Harrison Suppression of Inhibin A Biological Activity by Alterations in the Binding Site for Betaglycan J. Biol. Chem., June 13, 2008; 283(24): 16743 - 16751. [Abstract] [Full Text] [PDF]

				P. G. Farnworth, Y. Wang, R. Escalona, P. Leembruggen, G. T. Ooi, and J. K. Findlay Transforming Growth Factor-{beta} Blocks Inhibin Binding to Different Target Cell Types in a Context-Dependent Manner through Dual Mechanisms Involving Betaglycan Endocrinology, November 1, 2007; 148(11): 5355 - 5368. [Abstract] [Full Text] [PDF]

				M. Antenos, M. Stemler, I. Boime, and T. K. Woodruff N-Linked Oligosaccharides Direct the Differential Assembly and Secretion of Inhibin {alpha}- and {beta}A-Subunit Dimers Mol. Endocrinol., July 1, 2007; 21(7): 1670 - 1684. [Abstract] [Full Text] [PDF]